 Connection
Frank Scott to Cost-Benefit Analysis
This is a "connection" page, showing publications Frank Scott has written about Cost-Benefit Analysis.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.591 |
|
|
|
-
Scott FI, Hans AK, Gerich ME, Fennimore B, Mamtani R, Vajravelu RK, Lewis JD. Identification of the Most Effective Position for Ustekinumab in Treatment Algorithms for Crohn's Disease. Clin Gastroenterol Hepatol. 2021 10; 19(10):2082-2092.e10.
Score: 0.145
-
Scott FI, Luo M, Shah Y, Lasch K, Vajravelu RK, Mamtani R, Fennimore B, Gerich ME, Lewis JD. Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis. J Crohns Colitis. 2020 Jun 19; 14(5):575-587.
Score: 0.144
-
Johnson FR, Scott FI, Reed SD, Lewis JD, Bewtra M. Comparing the Noncomparable: The Need for Equivalence Measures That Make Sense in Health-Economic Evaluations. Value Health. 2019 06; 22(6):684-692.
Score: 0.133
-
Hans AK, Scott FI. Editorial: which inflammatory bowel disease patients should be screened for Epstein-Barr virus infection? Aliment Pharmacol Ther. 2018 11; 48(10):1158-1159.
Score: 0.129
-
Wang L, Scott FI, Boursi B, Reiss KA, Williams S, Glick H, Yang YX. Cost-Effectiveness of a Risk-Tailored Pancreatic Cancer Early Detection Strategy Among Patients With New-Onset Diabetes. Clin Gastroenterol Hepatol. 2022 09; 20(9):1997-2004.e7.
Score: 0.040
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|